Evidence map›Paper›PMID 42218511›Full record

ArticleAlzheimer's research & therapy2026

White matter

Huamei Lin, Ying Zhang, Ruiqing Ni, Min Wang, Jianwei Men, Jingjie Ge, Jiaying Lu, Jing Wang, Huiwei Zhang, Yunhao Yang and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Huamei Lin *Department of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Ying Zhang *School of Medicine, Shanghai University, Shanghai, China.
Ruiqing Ni *Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland.
Min WangInstitute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Jianwei MenInstitute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Jingjie GeDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Jiaying LuDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Jing WangDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Huiwei ZhangDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Yunhao YangDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Zhengwei ZhangDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Yuhua ZhuDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Hongguang ZhaoDepartment of Nuclear Medicine, The First Hospital of Jilin University, Changchun, Jilin, China.
Tzu-Chen YenDepartment of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
Junlong WangDepartment of Nuclear Medicine, Inselspital, University of Bern, Bern, Switzerland.
Kuangyu ShiDepartment of Nuclear Medicine, Inselspital, University of Bern, Bern, Switzerland.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, University of Bern, Bern, Switzerland.
Yihui GuanDepartment of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China.
Min Fang *Department of Neurology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China. fangmin_dr@126.com.
Jintai Yu *Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, 200040, China. jintai_yu@fudan.edu.cn.
Jiehui Jiang *Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China. jiangjiehui@shu.edu.cn.
Chuantao Zuo *Department of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, No.518, East Wuzhong Road, Shanghai, 200030, China. zuochuantao@fudan.edu.cn.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
National Natural Science Foundation of China 82021002, 82272039, and 82394434NIA NIH HHS U01 AG024904STI2030-Major Projects 2022ZD0211606
6 · The paper itself

Abstract

purposeWhite matter (WM) signal on ¹⁸F-florbetapir positron emission tomography (PET) is often regarded as nonspecific, yet its biological significance remains unclear. This study aimed to characterize the trajectory, clinical significance, and biomarker correlates of normal-appearing white matter (NAWM) ¹⁸F-florbetapir retention across the Alzheimer's disease (AD) continuum.

methodsWe analyzed NAWM ¹⁸F-florbetapir retention in 672 participants across the AD continuum from the Alzheimer's Disease Neuroimaging Initiative and two Chinese cohorts. Longitudinal PET, plasma, and cerebrospinal fluid (CSF) biomarkers, as well as lecanemab treatment effects, were evaluated.

resultsNAWM retention followed a distinct trajectory from cortical amyloid, increasing during preclinical stages and plateauing in symptomatic phases. Elevated NAWM ¹⁸F-florbetapir retention independently predicted cognitive decline, correlated with plasma p-tau217 and CSF p-tau/Aβ42 ratio, and showed significant reductions following lecanemab therapy. Combined assessment of cortical and NAWM PET improved diagnostic accuracy for amyloid positivity to 92%. NAWM retention also correlated strongly with plasma and CSF biomarkers in preclinical stages, and mediation analyses indicated that these fluid markers partly explained NAWM-cognition associations.

conclusionNAWM ¹⁸F-florbetapir retention represents a biologically valid and dynamic biomarker of AD progression, with potential utility for early detection, prognostication, and therapeutic monitoring.

Indexed as

Alzheimer DiseaseAniline CompoundsCognitive DysfunctionEthylene GlycolsWhite MatterAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersFemaleHumansLongitudinal StudiesMalePeptide FragmentsPositron-Emission Tomographytau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Aniline CompoundsBiomarkersEthylene GlycolsflorbetapirPeptide Fragmentstau Proteins18F-florbetapirAlzheimer’s diseaseBiomarkersCognitive declineNormal-appearing white matterRetention

Identifiers

PMID42218511
PMCPMC13436314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.